Anti-Thymocyte Globulin in Treatment of T-Cell Lymphoma

Rl, Edelson

doi:10.1016/s0140-6736(77)92867-7

Cited by 11 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, those improvements were disappointingly temporary, as new CTCL cell production continued, unimpeded by any immunologic defense. Similarly, we successfully reduced the systemic burden of malignant T cells through intravenous administration of anti-thymocyte globulin [5], but malignant T cell subclones resistant to the anti-T cell antibodies rapidly became dominant and lethal. These early interventions convinced my colleagues and me that, while individual T cell directed therapies had reportable clinical effects, they were merely temporary.…”

Section: Ecp’s Originmentioning

confidence: 99%

Mechanistic insights into extracorporeal photochemotherapy: Efficient induction of monocyte-to-dendritic cell maturation

Edelson

2014

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Extracorporeal photochemotherapy (ECP) is a widely used immunotherapy for cutaneous T cell lymphoma, as well as immunomodulation of graft-versus-host disease (GVHD) and transplanted organ rejection. ECP’s mechanism encompasses large-scale physiologic platelet induction of dendritic cells (DCs). The normal bidirectional immunologic talents of DCs likely contribute heavily to ECP’s capacity to immunize against tumor antigens, while also suppressing transplant immunopathology. Our understanding of how ECP physiologically induces monocyte-to-DC maturation can enhance the treatment’s potency, potentially broaden its use to other cancers and autoimmune disorders and tailor its application to individual patients’ diseases. ECP’s next decade is filled with promise.

show abstract

Section: Ecp’s Originmentioning

confidence: 99%

Mechanistic insights into extracorporeal photochemotherapy: Efficient induction of monocyte-to-dendritic cell maturation

Edelson

2014

Transfusion and Apheresis Science

View full text Add to dashboard Cite

show abstract

“…The patient with mycosis fungoides noted marked improvement in her skin disease, although repeated skin biopsies continued to reveal residual disease. 21 The ATG infusions were discontinued due to the sclerosing effect ,d the ATG and lack of venous access, and the patient subsequently died of progressive disease. Another patient with Sezary Syndrome was given ATG in an adjuvant fashion during chemotherapy induced thrombocytopenia.…”

Section: Discussionmentioning

confidence: 99%

The treatment of lymphoblastic lymphoma with antithymocyte globulin

Wong

Sweet

Variakojis

1982

Cancer

View full text Add to dashboard Cite

A 20‐year‐old man with previously treated lymphoblastic lymphoma, a known T‐cell disorder, developed progressive disease despite intensive combination chemotherapy with doxorubicin, vincristine, and prednisone. He was subsequently treated with a 21‐day course of intravenous antithymocyte globulin at a dose of approximately 15mg/kg per day. This resulted in a marked reduction in lymphadenopathy as determined by physical examination and chest X‐ray. Toxicity was limited to minor pruritis which resolved with diphenyldramine and hydrocortisone premedication. Cancer 50:57–61, 1982.

show abstract

“…Although the value of ALS as a therapeutic agent in these diseases appears to be limited, there is some evidence that it can reduce the number of circulating neoplastic cells in certain types of lymphoma and leukemia. Reduction in the count of peripheral blood T cells has been observed in a few patients with T-cell lymphoma who have been given ALS (Barrett et al 1976, Edelson et al 1977, Fisher et al 1978.…”

Section: Lymphoma and Leukemiamentioning

confidence: 99%

Clinical Experience with Antilymphocyte Serum

Heyworth

1982

Immunological Reviews

View full text Add to dashboard Cite

Many different antilymphocytic antisera have been used clinically, and the properties of any particular type of ALS are not necessarily identical to those of any other type. Nevertheless, it is possible to draw certain general conclusions about the effects of ALS in human subjects. ALS administration has often been shown to reduce the number of circulating E-rosette-positive lymphocytes, although the precise mechanisms by which this reduction occurs are not known. Using a combined technique of E-rosette formation and immunofluorescence, heterologous immunoglobulin has been demonstrated on T and non-T lymphocytes from patients receiving non-selective ALS. Fifteen years' experience has failed to provide convincing support for the view that ALS (including immunoglobulin prepared from the whole antiserum) prolongs human renal allograft survival. It is not yet known whether ALS is a useful immunosuppressive agent in cardiac transplantation. One observation of possible clinical interest is that bone marrow regeneration has occurred in a number of patients with aplastic anemia who have been treated with ALS. No satisfactory method has been developed for monitoring the dose of ALS in human subjects. Appropriate studies may determine whether monoclonal antilymphocytic antibodies are clinically useful, for example in prolonging the survival of transplanted organs, in preventing or treating graft-versus-host disease, or in treating lymphoma, leukemia, or aplastic anemia.

show abstract

Anti-Thymocyte Globulin in Treatment of T-Cell Lymphoma

Cited by 11 publications

References 0 publications

Mechanistic insights into extracorporeal photochemotherapy: Efficient induction of monocyte-to-dendritic cell maturation

Mechanistic insights into extracorporeal photochemotherapy: Efficient induction of monocyte-to-dendritic cell maturation

The treatment of lymphoblastic lymphoma with antithymocyte globulin

Clinical Experience with Antilymphocyte Serum

Contact Info

Product

Resources

About